Both ulcerative colitis and the other type of IBD, Crohn's disease, cause proctitis. About 30% of people with IBD have proctitis. Ulcerative colitis and Crohn’s disease are the most common ...

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...

A significant proportion of children newly diagnosed with IBD present with anaemia, and many of them remain anaemic even ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.

“Furthermore, these data strongly encourage us to pursue phase 2 clinical trials in other inflammatory indications including Crohn’s disease.” Ulcerative colitis is a debilitating ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

Previously approved for ulcerative ... vs. Stelara across four endoscopic or combined clinical and endoscopic endpoints.” It’s great to have another option for our patients with Crohn’s ...

2023 — Researchers have shown that changes can be detected in blood tests up to eight years before a diagnosis of Crohn's disease and up to three years before a diagnosis of ulcerative ...

For some people with ulcerative colitis (UC), consuming ... Another form of IBD is Crohn’s disease. Gastrointestinal (GI) symptoms may occur with UC, such as diarrhea and abdominal pain.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...